Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 2/2018

22.11.2017 | Original Article

Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II

verfasst von: Jitka Rybová, Jana Ledvinová, Jakub Sikora, Ladislav Kuchař, Robert Dobrovolný

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Mucopolysaccharidosis type II (MPSII) is a rare X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene (IDS, Xq28). MPSII is characterized by skeletal deformities, hearing loss, airway obstruction, hepatosplenomegaly, cardiac valvular disease, and progressive neurological impairment. At the cellular level, IDS deficiency leads to lysosomal storage of glycosaminoglycans (GAGs), dominated by accumulation of dermatan and heparan sulfates. Human induced pluripotent stem cells (iPSC) represent an alternative system that complements the available MPSII murine model. Herein we report on the reprogramming of peripheral white blood cells from male and female MPSII patients into iPSC using a non-integrating protocol based on the Sendai virus vector system. We differentiated the iPSC lines into IDS deficient and GAG accumulating β-Tubulin III+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes. The lysosomal system in these cells displayed structural abnormalities reminiscent of those previously found in patient tissues and murine IDS deficient neuronal stem cells. Furthermore, quantitative determination of GAGs revealed a moderate increase in GAG levels in IDS deficient neurons and glia. We also tested the effects of recombinant IDS and found that the exogenous enzyme was internalized from the culture media and partially decreased the intracellular GAG levels in iPSC-derived neural cells; however, it failed to completely prevent accumulation of GAGs. In summary, we demonstrate that this human iPSC based model expresses the cellular and biochemical features of MPSII, and thus represents a useful experimental tool for further pathogenesis studies as well as therapy development and testing.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat All AH, Gharibani P, Gupta S et al (2015) Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. PLoS One 10:e0116933CrossRefPubMedPubMedCentral All AH, Gharibani P, Gupta S et al (2015) Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. PLoS One 10:e0116933CrossRefPubMedPubMedCentral
Zurück zum Zitat Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM (2013) Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 24:1741–1749CrossRefPubMed Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM (2013) Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 24:1741–1749CrossRefPubMed
Zurück zum Zitat Canfield SG, Stebbins MJ, Morales BS et al (2017) An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem 140:874–888CrossRefPubMed Canfield SG, Stebbins MJ, Morales BS et al (2017) An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem 140:874–888CrossRefPubMed
Zurück zum Zitat Cardone M, Polito VA, Pepe S et al (2006) Correction of hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15:1225–1236CrossRefPubMed Cardone M, Polito VA, Pepe S et al (2006) Correction of hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15:1225–1236CrossRefPubMed
Zurück zum Zitat Chen J, Riazifar H, Guan MX, Huang T (2016) Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets. Stem Cell Res Ther 7:2CrossRefPubMedPubMedCentral Chen J, Riazifar H, Guan MX, Huang T (2016) Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets. Stem Cell Res Ther 7:2CrossRefPubMedPubMedCentral
Zurück zum Zitat Fusar Poli E, Zalfa C, D'Avanzo F et al (2013) Murine neural stem cells model hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved. Cell Death Dis 4:e906CrossRefPubMedPubMedCentral Fusar Poli E, Zalfa C, D'Avanzo F et al (2013) Murine neural stem cells model hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved. Cell Death Dis 4:e906CrossRefPubMedPubMedCentral
Zurück zum Zitat Gallagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34:438–441CrossRefPubMed Gallagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34:438–441CrossRefPubMed
Zurück zum Zitat Gomes IC, Acquarone M, Maciel Rde M, Erlich RB, Rehen SK (2010) Analysis of pluripotent stem cells by using cryosections of embryoid bodies. J Vis Exp. doi: 10.3791/2344 Gomes IC, Acquarone M, Maciel Rde M, Erlich RB, Rehen SK (2010) Analysis of pluripotent stem cells by using cryosections of embryoid bodies. J Vis Exp. doi: 10.3791/2344
Zurück zum Zitat Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422–427CrossRefPubMed Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422–427CrossRefPubMed
Zurück zum Zitat Itier JM, Ret G, Viale S et al (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis 37:1013–1022CrossRefPubMed Itier JM, Ret G, Viale S et al (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis 37:1013–1022CrossRefPubMed
Zurück zum Zitat Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A et al (2016) Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed) 21:1393–1409CrossRef Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A et al (2016) Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed) 21:1393–1409CrossRef
Zurück zum Zitat Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ (2013) The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab 109:41–48CrossRefPubMed Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ (2013) The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab 109:41–48CrossRefPubMed
Zurück zum Zitat de Jong JG, Wevers RA, Liebrand-van Sambeek R (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMed de Jong JG, Wevers RA, Liebrand-van Sambeek R (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMed
Zurück zum Zitat Meier C, Wismann U, Herschkowitz N, Bischoff A (1979) Morphological observations in the nervous system of prenatal mucopolysaccharidosis II (M. Hunter). Acta Neuropathol 48:139–143CrossRefPubMed Meier C, Wismann U, Herschkowitz N, Bischoff A (1979) Morphological observations in the nervous system of prenatal mucopolysaccharidosis II (M. Hunter). Acta Neuropathol 48:139–143CrossRefPubMed
Zurück zum Zitat Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y (2010) Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 107:7886–7891CrossRefPubMedPubMedCentral Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y (2010) Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 107:7886–7891CrossRefPubMedPubMedCentral
Zurück zum Zitat Motas S, Haurigot V, Garcia M et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (hunter syndrome). JCI Insight 1:e86696CrossRefPubMedPubMedCentral Motas S, Haurigot V, Garcia M et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (hunter syndrome). JCI Insight 1:e86696CrossRefPubMedPubMedCentral
Zurück zum Zitat Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (hunter syndrome): a preliminary report. Acta Paediatr Suppl 91:98–99CrossRefPubMed Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (hunter syndrome): a preliminary report. Acta Paediatr Suppl 91:98–99CrossRefPubMed
Zurück zum Zitat Muenzer J, Beck M, Eng CM et al (2011) Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Gen Med: Off J Am Coll Med Gen 13:95–101 Muenzer J, Beck M, Eng CM et al (2011) Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Gen Med: Off J Am Coll Med Gen 13:95–101
Zurück zum Zitat Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452 Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452
Zurück zum Zitat Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215–224CrossRefPubMed Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215–224CrossRefPubMed
Zurück zum Zitat Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25 Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25
Zurück zum Zitat Patel P, Suzuki Y, Tanaka A et al (2014) Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Gen Metab Rep 1:184–196 Patel P, Suzuki Y, Tanaka A et al (2014) Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Gen Metab Rep 1:184–196
Zurück zum Zitat Perrimon N, Bernfield M (2001) Cellular functions of proteoglycans--an overview. Semin Cell Dev Biol 12:65–67CrossRefPubMed Perrimon N, Bernfield M (2001) Cellular functions of proteoglycans--an overview. Semin Cell Dev Biol 12:65–67CrossRefPubMed
Zurück zum Zitat Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefPubMedPubMedCentral Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefPubMedPubMedCentral
Zurück zum Zitat Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrao-Braga PC (2015) Induced pluripotent stem cells for modeling neurological disorders. World J Transplant 5:209–221CrossRefPubMedPubMedCentral Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrao-Braga PC (2015) Induced pluripotent stem cells for modeling neurological disorders. World J Transplant 5:209–221CrossRefPubMedPubMedCentral
Zurück zum Zitat Skoog WA, Beck WS (1956) Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11:436–454PubMed Skoog WA, Beck WS (1956) Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11:436–454PubMed
Zurück zum Zitat Stacpoole SR, Bilican B, Webber DJ et al (2011) Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen. Nat Protoc 6:1229–1240CrossRefPubMedPubMedCentral Stacpoole SR, Bilican B, Webber DJ et al (2011) Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen. Nat Protoc 6:1229–1240CrossRefPubMedPubMedCentral
Zurück zum Zitat Tanaka A, Okuyama T, Suzuki Y et al (2012) Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 107:513–520CrossRefPubMed Tanaka A, Okuyama T, Suzuki Y et al (2012) Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 107:513–520CrossRefPubMed
Zurück zum Zitat Varki A (1999) Essentials of glycobiology, vol xvii. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p 653 Varki A (1999) Essentials of glycobiology, vol xvii. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p 653
Zurück zum Zitat Voznyi YV, Keulemans JL, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (hunter disease). J Inherit Metab Dis 24:675–680CrossRefPubMed Voznyi YV, Keulemans JL, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (hunter disease). J Inherit Metab Dis 24:675–680CrossRefPubMed
Zurück zum Zitat Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N (1980) Prenatal mucopolysaccharidosis II (hunter): a pathogenetic study. Pediatr Res 14:749–756CrossRefPubMed Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N (1980) Prenatal mucopolysaccharidosis II (hunter): a pathogenetic study. Pediatr Res 14:749–756CrossRefPubMed
Zurück zum Zitat Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefPubMed Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefPubMed
Metadaten
Titel
Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II
verfasst von
Jitka Rybová
Jana Ledvinová
Jakub Sikora
Ladislav Kuchař
Robert Dobrovolný
Publikationsdatum
22.11.2017
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 2/2018
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0108-5

Weitere Artikel der Ausgabe 2/2018

Journal of Inherited Metabolic Disease 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.